Basilea was initially spun out from Roche as an anti-infectives focussed enterprise. While Cresemba has undoubtedly been a success, progress for antibiotic ceftobiprole has been less impressive. Ceftobiprole is approved outside the US for the treatment of HAP/CAP, but the lack of a VAP indication has constrained sales. Our report examines how this could be about to change.
